Cerebrospinal fluid (CSF), due to its immediate proximity to the central nervous system, offers a high diagnostic potential. However, CFS samples require novel technologies due to low analyte concentrations. This project will create a modular low-input omics platform that combines innovative microfluidic separation of very low cell counts with fluorescence-based detection using selective, high-affinity aptamers, as well as state-of-the-art molecular analyses of minimal amounts of proteins, metabolites, and DNA. The platform will be validated in clinical networks based on two use cases: mutation detection in CSF for LM (leptomeningeal metastases) and the identification and validation of predictive biomarkers for disease progression in MS (multiple sclerosis). Potential clients range from pharmaceutical and biotech companies to diagnostic and cell sorting technology providers who benefit from new binding molecules, selective cell separation, and validated biomarker methods.